Jim joined Venture Investors in 2006 as a Managing Director, and heads up the Ann Arbor, Michigan office. He leverages his technical, operational and venture capital background by focusing on investment prospects in medical devices, diagnostics, and healthcare IT.
Jim currently serves as Chairman of the Board of Directors of HistoSonics, a company Venture Investors spun out of the University of Michigan and led the $15M Series A financing. In addition, Jim currently serves on the Boards of ViaLase and SkySpecs. He was previously Chairman of the Board of Directors of Tissue Regeneration Systems (TRS), where he was a co-Founder and the Company’s first CEO (acquired by Johnson & Johnson and Medtronic). Jim was previously Board Observer of NeuMoDx Molecular (acquired by Qiagen for $310M) and LenSx (acquired by Alcon for up to $744M).
Jim’s prior venture capital experience includes a combined nine years as a partner at RidgeLine Ventures and EDF Ventures.
Prior to his venture capital positions, Jim had nine years operating experience both domestically and internationally. In these roles, he wore many functional hats: marketing, engineering, business development and operations. Jim is fluent in Spanish.
Jim is a competitive triathlete, and a five-time Ironman finisher. He is a cyclocross and mountain bike rider and racer, and a 10-time Iceman finisher. He is part of Venture Investors’ American Birkebeiner cross-country ski “team.” In his free time, he enjoys adventures with his family and photography.